Sanofi

🎉 We've just released our Sanofi Patient Community Promise 2024 Report! Launched in 2023, the Promise is our commitment to partner with patients—not just for them. We're proud to be the first pharmaceutical company to publicly report on patient engagement metrics co-created with the patient community. Over the past year, we've made real progress in areas like R&D, while identifying where we must go further, especially around simplifying processes. This report reflects our journey—what's working, what's not, and how patient voices continue to shape the way we operate. At Sanofi, we don't just act FOR patients, we act WITH them as equal partners. Read our new Patient Community Promise Report here 👉 http://spkl.io/6041AESrJ

This summer, we’re proud to bring the Paris 2024™ spirit to life with Zeus, the legendary horse, as he gallops to the iconic Mont-Saint-Michel. 🇫🇷 Through the #SanofiTour, we’re celebrating strength, movement, and the power to inspire every generation—wherever dreams take us. 🐎✨ Atelier blam #Paris2024

From biologics to mRNA, biology has entered a new era—one where AI is redefining what is possible in medicine. Today, AI is not just accelerating scientific discovery; it’s reshaping how we understand, prevent and treat disease. Global Head of Preclinical Computational Innovation Strategy Maria Wendt and Head of Data and Computational Sciences Fernando Ulloa Montoya discuss the powerful combination of human ingenuity and artificial intelligence that is helping move from what once seemed like science fiction to reality as we work to bring safer, more effective medicines and vaccines to patients faster than ever before: http://spkl.io/6047ADk61 #WeNeverSettle #AI #DrugDiscovery

#WhoopingCough isn't just a childhood disease. It’s an extremely contagious threat for adults too. Heidi’s story shows the reality of whooping cough in adults with underlying conditions - a growing public health concern even in countries with high childhood immunization rates. 👉 Watch her story to learn more about whooping cough. #PublicHealth #VaccinesWork #Pertussis

Japan’s Ministry of Health, Labour and Welfare granted orphan drug designation for Sanofi’s investigational treatment for people living with chronic inflammatory demyelinating polyneuropathy (CIDP).    This designation brings us one step closer to hopefully addressing the unmet need for patients living with #CIDP. Our goal is to help people live for the moment, not the disease.     Read our press release ➡️ https://lnkd.in/e3SVkSnS

🌈 As Pride Month wraps up, we’re proud to celebrate the spirit of inclusion that unites Sanofians around the world. From raising Pride flags to hosting global conversations, our Pride+ network and 20+ LGBTQ+ ERGs have shown that inclusion at Sanofi is more than a moment—it’s a movement. Inclusion fuels innovation strengthens our teams and helps us better serve patients. And while Pride Month ends, our commitment continues—every day, all year. #PrideMonth #Inclusion

We’re proud to be ranked 10th overall and #1 in the Pharma & Biotech industries on TIME's 2025 list of the World’s 500 Most Sustainable Companies! Our commitment to sustainability goes far beyond delivering innovative medicines — from improving access to healthcare and reducing the environmental impact of our products to building resilience in healthcare systems. Learn more about how we’re working to protect both people and the planet ➡️ http://spkl.io/6048ABKrq #Sustainability

The FDA has granted Orphan Drug Designation to our investigational treatment for antibody-mediated rejection (AMR) in solid organ transplantation. This designation reflects our commitment to addressing a critical unmet need in transplant medicine, where AMR remains a significant challenge with no FDA-approved treatments available. Read the full press release: http://spkl.io/6045A6sIb

We were proud to partner with McLaren Racing and United Autosports at the legendary 2025 #LeMans24 — where passion met purpose on and off the track. 🎥 Watch the highlights and relive the unforgettable moments — because this is a story we’ll carry with us forever. #DefeatMeningitis #MeningitisFlag

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) recommended the approval of our #MultipleMyeloma combination therapy to treat transplant-eligible, newly diagnosed patients. If approved, the decision would represent the fourth indication for our medicine in the European Union and second indication in the front-line setting. Read our press release: https://lnkd.in/e5sE6rVi